Profile data is unavailable for this security.
About the company
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
- Revenue in USD (TTM)87.00k
- Net income in USD-4.95m
- Incorporated1992
- Employees4.00
- LocationTitan Pharmaceuticals IncSUITE 505, 400 OYSTER POINT BLVDSAN FRANCISCO 94080United StatesUSA
- Phone+1 (415) 244-4990
- Fax+1 (650) 244-4956
- Websitehttps://www.titanpharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kineta Inc | 5.16m | -17.89m | 5.69m | 11.00 | -- | -- | -- | 1.10 | -1.55 | -1.55 | 0.4673 | -0.564 | 0.6667 | -- | -- | 469,181.80 | -230.51 | -66.16 | -- | -86.61 | -- | -- | -345.77 | -854.74 | -- | -- | -- | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -16.10m | 5.70m | 8.00 | -- | 0.2865 | -- | -- | -14.03 | -14.17 | 0.00 | 19.06 | 0.00 | -- | -- | 0.00 | -49.97 | -- | -53.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| Hoth Therapeutics Inc | 0.00 | -7.70m | 5.72m | 2.00 | -- | 0.6578 | -- | -- | -2.02 | -2.02 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -70.17 | -157.07 | -77.15 | -177.32 | -- | -- | -- | -- | -- | -50.67 | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
| Glucose Health Inc | 1.11m | -456.46k | 5.80m | 2.00 | -- | 6.12 | -- | 5.21 | -0.033 | -0.033 | 0.0803 | 0.0561 | -- | -- | -- | -- | -- | -86.94 | -- | -153.95 | 47.19 | 40.68 | -31.99 | -56.93 | 313.11 | -- | 0.00 | -- | 98.39 | 24.94 | 16.87 | -- | -- | -- |
| AiXin Life International Inc | 4.09m | -2.09m | 5.82m | 207.00 | -- | -- | -- | 1.42 | -0.0836 | -0.0836 | 0.1636 | -0.0765 | 0.8268 | 5.43 | 10.02 | 19,757.49 | -42.27 | -16.93 | -- | -34.54 | 16.25 | 48.13 | -51.12 | -36.96 | 0.1515 | -- | -- | -- | 51.00 | 58.08 | 67.18 | -- | 194.59 | -- |
| Silo Pharma Inc | 72.12k | -3.53m | 5.83m | 3.00 | -- | 1.11 | -- | 80.85 | -1.18 | -1.20 | 0.024 | 1.87 | 0.008 | -- | -- | 24,040.00 | -39.26 | -24.90 | -43.11 | -26.39 | 91.90 | 82.79 | -4,889.57 | -2,757.85 | -- | -- | 0.00 | -- | 0.00 | -- | 7.07 | -- | -- | -- |
| Protagenic Therapeutics Inc | 0.00 | -6.01m | 5.85m | -- | -- | 2.75 | -- | -- | -1.37 | -1.37 | 0.00 | 0.4808 | 0.00 | -- | -- | -- | -117.26 | -74.49 | -140.56 | -92.56 | -- | -- | -- | -- | -- | -11.50 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 9.00k | -5.28m | 5.86m | 4.00 | -- | 0.6385 | -- | 651.59 | -3.74 | -3.74 | 0.0064 | 6.81 | 0.0007 | 0.4291 | -- | 2,250.00 | -42.47 | -110.00 | -43.88 | -- | 60.00 | 65.82 | -58,624.33 | -7,961.14 | 23.53 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| Titan Pharmaceuticals Inc | 87.00k | -4.95m | 5.95m | 4.00 | -- | 0.978 | -- | 68.41 | -6.41 | -6.41 | 0.1119 | 6.66 | 0.0197 | -- | 1.23 | 21,750.00 | -112.41 | -96.80 | -170.59 | -156.65 | -- | -- | -5,694.25 | -406.26 | -- | -415.19 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| Virios Therapeutics Inc | 0.00 | -5.07m | 5.97m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.44m | -4.47m | 6.01m | 4.00 | -- | 0.6926 | -- | 2.46 | -2.92 | -2.92 | 1.59 | 5.63 | 0.2116 | -- | -- | 611,240.00 | -38.71 | -48.91 | -41.54 | -52.82 | -- | -- | -182.95 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
| Enveric Biosciences Inc | 0.00 | -15.11m | 6.05m | 7.00 | -- | 0.8777 | -- | -- | -6.46 | -6.46 | 0.00 | 0.8887 | 0.00 | -- | -- | 0.00 | -122.02 | -104.94 | -178.49 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| Applied DNA Sciences Inc | 5.52m | -12.50m | 6.09m | 53.00 | -- | -- | -- | 1.10 | -17.13 | -17.13 | 7.67 | -0.0558 | 0.3893 | 10.38 | 4.64 | 104,110.80 | -87.15 | -88.57 | -111.09 | -121.91 | 33.98 | 44.35 | -223.89 | -113.26 | 1.54 | -- | -- | -- | -26.43 | 27.92 | -18.73 | -- | 33.80 | -- |
| Adial Pharmaceuticals Inc | 0.00 | -11.24m | 6.14m | 4.00 | -- | 0.9605 | -- | -- | -6.01 | -3.75 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -212.33 | -182.35 | -273.26 | -235.45 | -- | -- | -- | -- | -- | -20.20 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 6.23m | 389.00 | 0.0011 | 0.0001 | 0.6752 | 0.1094 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
Data as of May 30 2024. Currency figures normalised to Titan Pharmaceuticals Inc's reporting currency: US Dollar USD
3.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Truist Bank (Private Banking)as of 31 Mar 2024 | 31.25k | 3.42% |
| Tower Research Capital LLCas of 31 Mar 2024 | 647.00 | 0.07% |
| MCF Advisors LLCas of 31 Mar 2024 | 165.00 | 0.02% |
| Group One Trading LPas of 31 Mar 2024 | 12.00 | 0.00% |
| BofA Securities, Inc.as of 31 Mar 2024 | 11.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 6.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 5.00 | 0.00% |
| American Portfolios Advisors, Inc.as of 31 Mar 2024 | 3.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 3.00 | 0.00% |
| Global Wealth Strategies & Associates LLCas of 31 Mar 2024 | 2.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
